Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, 6525 EX, Netherlands
NCT Number: NCT01779609
The purpose of this study is to establish the effect of ET blockade on vascular adaptations during an 8-week exercise program in subjects with T2DM. We hypothesize that combining ET - blockade with exercise training leads to an acute increase of exercise induced blood flow when compared with exercise alone. We expect that this will lead to an optimization of vascular training effect in T2DM.
Looking for future studies?
Notify Me40 year–65 year
Male
Interventional
Phase 4
Nijmegen, Gelderland, 6525 EX, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Tracleer, actelion pharmaceuticals
Other names: actelion pharmaceuticals
Supervised exercise training program of 8 weeks, for 3x/week
Other names: Supervised Exercise Training Program
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Radboud University Medical Center
Other
Effect of a Dual ET(Endothelin)-Blocker on Exercise Induced Vascular Adaptations in Type 2 Diabetes Mellitus (T2DM)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00467285
Bone Diseases, Bone Diseases, Metabolic
View Trial DetailsNCT02538848
Diabetes Mellitus, Diabetes Mellitus, Type 2
Perth, Australia
View Trial DetailsNCT06353347
Diabetes Mellitus, Diabetes Mellitus, Type 2
Baotou, China
View Trial DetailsNCT05637437
Diabetes Mellitus, Diabetes Mellitus, Type 2
Serdang, Selangor, Malaysia
View Trial Details